Non hematologic adverse effect considered when switching TKI
PULMONARY HYPERTENSION
DASATINIB
Non hematologic adverse effect considered when switching TKI
RECURRENT PLEURAL AND PERICARDIAL EFFUSION DESPITE DOSE REDUCTION
DASATINIB
less common with bosutinib
Non hematologic adverse effect considered when switching TKI
SEVERE HYPERTENSION NOT RESPONSIVE TO ANTIHYPERTENSIVE MEDICATION
PONATINIB AND ASCIMINIB
Non hematologic adverse effect considered when switching TKI
ARTERIAL AND VASCULAR ADVERSE EVENTS
MORE COMMON WITH NILOTINIB AND PONATINIB
Non hematologic adverse effect considered when switching TKI
HYPERGLYCEMIA
MOST COMMON WITH NILOTINIB
Non hematologic adverse effect considered when switching TKI
RECURRENT PANCREATITIS DESPITE DOSE REDUCTION
MOST COMMON WITH NILOTINIB, PONATINIB, ASCIMINIB
Non hematologic adverse effect considered when switching TKI
GASTROINTESTINAL BLEEDING
DASATINIB
Non hematologic adverse effect considered when switching TKI
LIVER FUNCTION TEST ABNORMALITIES
MORE COMMON WITH BOSUTINIB AND IMATINIB
CML treatment for pregnant patients
Interferon alpha
